Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/ (accessed on 12 April 2022).
- Walsh, K.A.; Spillane, S.; Comber, L.; Cardwell, K.; Harrington, P.; Connell, J.; Teljeur, C.; Broderick, N.; de Gascun, C.F.; Smith, S.M.; et al. The duration of infectiousness of individuals infected with SARS-CoV-2. J. Infect. 2020, 81, 847–856. [Google Scholar] [CrossRef] [PubMed]
- Truong, T.T.; Ryutov, A.; Pandey, U.; Yee, R.; Goldberg, L.; Bhojwani, D.; Aguayo-Hiraldo, P.; Pinsky, B.A.; Pekosz, A.; Shen, L.; et al. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine 2021, 67, 103355. [Google Scholar] [CrossRef] [PubMed]
- Ma, M.J.; Qiu, S.F.; Cui, X.M.; Ni, M.; Liu, H.; Ye, R.; Yao, L.; Liu, H.; Cao, W.; Song, H. Persistent SARS-CoV-2 infection in asymptomatic young adults. Signal Transduct. Target. Ther. 2022, 7, 77. [Google Scholar] [CrossRef] [PubMed]
- Owusu, D.; Pomeroy, M.A.; Lewis, N.M.; Wadhwa, A.; Yousaf, A.R.; Whitaker, B.; Dietrich, E.; Hall, A.J.; Chu, V.; Thornburg, N.; et al. Persistent SARS-CoV-2 RNA Shedding without Evidence of Infectiousness: A Cohort Study of Individuals with COVID-19. J. Infect. Dis. 2021, 224, 1362–1371. [Google Scholar] [CrossRef]
- Li, Q.; Zheng, X.S.; Shen, X.R.; Si, H.; Wang, X.; Wang, Q.; Li, B.; Zhang, W.; Zhu, Y.; Jiang, R.; et al. Prolonged shedding of severe acute respiratory syndrome coronavirus 2 in patients with COVID-19. Emerg. Microbes Infect. 2020, 9, 2571–2577. [Google Scholar] [CrossRef]
- Consorcio Genomas COV-2. Secuencias de SARS-CoV-2 de Chile. Available online: https://auspice.cov2.cl/ncov/chile-global (accessed on 15 August 2022).
- Barrera-Avalos, C.; Luraschi, R.; Vallejos-Vidal, E.; Figueroa, M.; Arenillas, E.; Barría, D.; Hernández, F.; Mateluna, C.; Mena, J.; Rioseco, C.; et al. Analysis by real-time PCR of five transport and conservation mediums of nasopharyngeal swab samples to COVID-19 diagnosis in Santiago of Chile. J. Med. Virol. 2022, 94, 1167–1174. [Google Scholar] [CrossRef]
- Barrera-Avalos, C.; Luraschi, R.; Vallejos-Vidal, E.; Mella-Torres, A.; Hernández, F.; Figueroa, M.; Rioseco, C.; Valdés, D.; Imarai, M.; Acuña-Castillo, C.; et al. The Rapid Antigen Detection Test for SARS-CoV-2 Underestimates the Identification of COVID-19 Positive Cases and Compromises the Diagnosis of the SARS-CoV-2 (K417N/T, E484K, and N501Y) Variants. Front. Public Health 2022, 9, 780801. [Google Scholar] [CrossRef]
- Jones, D.T.; Taylor, W.R.; Thornton, J.M. The rapid generation of mutation data matrices from protein sequences. Bioinformatics 1992, 8, 275–282. [Google Scholar] [CrossRef]
- Kumar, S.; Stecher, G.; Li, M.; Knyaz, C.; Tamura, K. MEGA X: Molecular Evolutionary Genetics Analysis across Computing Platforms. Mol. Biol. Evol. 2018, 35, 1547–1549. [Google Scholar] [CrossRef]
- Stecher, G.; Tamura, K.; Kumar, S. Molecular Evolutionary Genetics Analysis (MEGA) for macOS. Mol. Biol. Evol. 2020, 37, 1237–1239. [Google Scholar] [CrossRef]
- Zahn, T.; Mhedhbi, I.; Hein, S.; Raupach, J.; Miskey, C.; Husria, Y.; Bayanga, K.; Bartel, D.; Vieths, S.; Ivics, Z.; et al. Persistence of infectious SARS-CoV-2 particles for up to 37 days in patients with mild COVID-19. Allergy Eur. J. Allergy Clin. Immunol. 2021, 77, 2053–2066. [Google Scholar] [CrossRef]
- Zupin, L.; Fontana, F.; Clemente, L.; Boschian-Bailo, P.; Ruscio, M.; Crovella, S. Persistent viral infectivity after 27 days from COVID-19 symptoms onset. J. Clin. Pathol. 2022, 75, 211–214. [Google Scholar] [CrossRef] [PubMed]
- Li, N.; Wang, X.; Lv, T. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. J. Med. Virol. 2020, 92, 2286–2287. [Google Scholar] [CrossRef] [PubMed]
- Desimmie, B.A.; Raru, Y.Y.; Awadh, H.M.; He, P.; Teka, S.; Willenburg, K.S. Insights into SARS-CoV-2 persistence and its relevance. Viruses 2021, 13, 1025. [Google Scholar] [CrossRef] [PubMed]
- Zhou, C.; Zhang, T.; Ren, H.; Sun, S.; Yu, X.; Sheng, J.; Shi, Y.; Zhao, H. Impact of age on duration of viral RNA shedding in patients with COVID-19. Aging 2020, 12, 22399–22404. [Google Scholar] [CrossRef]
- Carmo, A.; Pereira-Vaz, J.; Mota, V.; Mendes, A.; Morais, C.; da Silva, A.C.; Camilo, E.; Pinto, C.S.; Cunha, E.; Pereira, J.; et al. Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19. J. Med. Virol. 2020, 92, 2227–2231. [Google Scholar] [CrossRef]
- Department of Epidemiology. Epidemiological Report N°14 Genomic Surveillance of SARS-CoV-2 (COVID-19) Chile September 20, 2021. 2021. Available online: minsal.cl/wp-content/uploads/2021/09/Informe-Variantes-N14-20092020.pdf (accessed on 16 August 2022).
- Sergey, S.; Alexey, V. Could COVID-19 be a latent viral infection? Glob. J. Infect. Dis. Clin. Res. 2020, 6, 29–30. [Google Scholar] [CrossRef]
- Goldberg, Y.; Mandel, M.; Bar-On, Y.M.; Bodenheimer, O.; Freedman, L.S.; Ash, N.; Alroy-Preis, S.; Huppert, A.; Milo, R. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N. Engl. J. Med. 2022, 386, 2201–2212. [Google Scholar] [CrossRef]
- Suah, J.L.; Husin, M.; Tok, P.S.K.; Tng, B.H.; Thevananthan, T.; Low, E.V.; Appannan, M.R.; Zin, F.M.; Zin, S.M.; Yahaya, H.; et al. Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. Int. J. Infect. Dis. 2022, 119, 69–76. [Google Scholar] [CrossRef]
- Lan, L.; Xu, D.; Ye, G.; Xia, C.; Wang, S.; Li, Y.; Xu, H. Positive RT-PCR Test Results in Patients Recovered from COVID-19. JAMA 2020, 323, 1502. [Google Scholar] [CrossRef]
- Tang, X.; Musa, S.S.; Zhao, S.; He, D. Reinfection or Reactivation of Severe Acute Respiratory Syndrome Coronavirus 2: A Systematic Review. Front. Public Health 2021, 9, 663045. [Google Scholar] [CrossRef] [PubMed]
- Bakhshandeh, B.; Jahanafrooz, Z.; Abbasi, A.; Golia, M.B.; Sadeghi, M.; Mottaqi, M.S.; Zamani, M. Mutations in SARS-CoV-2; Consequences in structure, function, and pathogenicity of the virus. Microb. Pathog. 2021, 154, 104831. [Google Scholar] [CrossRef]
- Ogawa, J.; Zhu, W.; Tonnu, N.; Singer, O.; Hunter, T.; Ryan, A.L.; Pao, G.M. The D614G mutation in the SARS-CoV2 Spike protein increases infectivity in an ACE2 receptor dependent manner. BioRxiv 2020. [Google Scholar] [CrossRef]
- Self, W.H.; Tenforde, M.W.; Stubblefield, W.B.; Feldstein, L.R.; Steingrub, J.S.; Shapiro, N.I.; Ginde, A.A.; Prekker, M.E.; Brown, S.M.; Peltan, I.D.; et al. Decline in SARS-CoV-2 Antibodies after Mild Infection among Frontline Health Care Personnel in a Multistate Hospital Network—12 States, April–August 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1762–1766. [Google Scholar] [CrossRef]
- Feikin, D.R.; Higdon, M.M.; Abu-Raddad, L.J.; Andrews, N.; Araos, R.; Goldberg, Y.; Groome, M.J.; Huppert, A.; O’Brien, K.L.; Smith, P.P.G.; et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet 2022, 399, 924–944. [Google Scholar] [CrossRef] [PubMed]
- Canaday, D.H.; Oyebanji, O.A.; Keresztesy, D.; Payne, M.; Wilk, D.; Carias, L.; Aung, H.; Denis, K.S.; Lam, E.C.; Rowley, C.F.; et al. Significant Reduction in Vaccine-Induced Antibody Levels and Neutralization Activity among Healthcare Workers and Nursing Home Residents 6 Months Following Coronavirus Disease 2019 BNT162b2 mRNA Vaccination. Clin. Infect. Dis. 2022, 75, e884–e887. [Google Scholar] [CrossRef] [PubMed]
- Bianco, A.; Capozzi, L.; del Sambro, L.; Simone, D.; Pace, L.; Rondinone, V.; Difato, L.M.; Miccolupo, A.; Manzari, C.; Fedele, A.; et al. Persistent SARS-CoV-2 Infection in a Patient with Non-hodgkin Lymphoma: Intra-Host Genomic Diversity Analysis. Front. Virol. 2022, 2, 758191. [Google Scholar] [CrossRef]
- Goërtz, Y.M.J.; van Herck, M.; Delbressine, J.M.; Vaes, A.W.; Meys, R.; Machado, F.V.C.; Houben-Wilke, S.; Burtin, C.; Posthuma, R.; Franssen, F.M.E.; et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 2020, 6, 542–2020. [Google Scholar] [CrossRef]
0806-191 | 230921-099 | ||||
---|---|---|---|---|---|
Genome Location | SNVs | Amino Acid Substitution | Genome Location | SNVs | Amino Acid Substitution |
241 | C->T | n/a | 241 | C->T | n/a |
3037 | C->T | n/a | |||
6402 | C->T | n/a | |||
6479 | G->A | n/a | 6479 | G->A | n/a |
6706 | C->T | ORF1a:V2072I | |||
8043 | C->A | n/a | |||
10511 | G->C | n/a | |||
14408 | C->T | ORF1b:P314L | 14408 | C->T | ORF1b:P314L |
15451 | G->T | n/a | |||
17699 | T->C | ORF1b:I1411T | |||
18457 | C->T | ORF1b:P1664S | |||
22088 | C->T | S:L176F | |||
23403 | A->G | S:D614G | |||
27137 | A->G | n/a | 27137 | A->G | n/a |
27604 | G->A | ORF7a:V71I | |||
27638 | T->C | ORF7a:V82A | |||
27670 | G->T | ORF7a:V93F | |||
27752 | C->T | ORF7a:T120I | |||
Δ 28248-28253 | GATTTC | n/a | |||
Δ 28273 | A | n/a | |||
Δ3590 | A | n/a |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Acuña-Castillo, C.; Maisey, K.; Vidal, M.; Barrera-Avalos, C.; Inostroza-Molina, A.; Luraschi, R.; Vallejos-Vidal, E.; Valdés, D.; Imarai, M.; Reyes-López, F.E.; et al. Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile. Infect. Dis. Rep. 2022, 14, 971-978. https://doi.org/10.3390/idr14060096
Acuña-Castillo C, Maisey K, Vidal M, Barrera-Avalos C, Inostroza-Molina A, Luraschi R, Vallejos-Vidal E, Valdés D, Imarai M, Reyes-López FE, et al. Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile. Infectious Disease Reports. 2022; 14(6):971-978. https://doi.org/10.3390/idr14060096
Chicago/Turabian StyleAcuña-Castillo, Claudio, Kevin Maisey, Mabel Vidal, Carlos Barrera-Avalos, Ailen Inostroza-Molina, Roberto Luraschi, Eva Vallejos-Vidal, Daniel Valdés, Mónica Imarai, Felipe E. Reyes-López, and et al. 2022. "Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile" Infectious Disease Reports 14, no. 6: 971-978. https://doi.org/10.3390/idr14060096
APA StyleAcuña-Castillo, C., Maisey, K., Vidal, M., Barrera-Avalos, C., Inostroza-Molina, A., Luraschi, R., Vallejos-Vidal, E., Valdés, D., Imarai, M., Reyes-López, F. E., & Sandino, A. M. (2022). Genomic Evidence Suggests Viral Persistence of SARS-CoV-2 for 386 Days in Health Worker: A Case Report from Santiago of Chile. Infectious Disease Reports, 14(6), 971-978. https://doi.org/10.3390/idr14060096